ThermoGenesis Holdings (THMO): חובות להיוון בספרים

ThermoGenesis generates revenue through the sale of cryopreservation and cell separation systems, securing a steady cash flow from services and consumables. The debt-to-capitalization ratio on the balance sheet reflects borrowing trends, where 7.90 marks a new level. Business growth is driven by demand in the cell therapy sector and strict GMP compliance. Stable plant operations and equipment upgrades ensure high production continuity.

Asset managers are evaluating the operating model of ThermoGenesis (THMO) through the lens of financial stability. This metric determines the proportion of borrowed funds relative to equity, measuring the business's degree of debt load. By analyzing the capital structure trend—debt to book capitalization—the investor sees the actual financing leverage. For a company subject to strict FDA control and patent protection, low leverage guarantees survival. This confirms the fundamental strength of the issuer's position.